“CDMO” has quietly replaced “OEM” in skincare sourcing conversations, and the shift matters. A contract development and manufacturing organization does more than fill a jar to your label — the better ones run their own formulation R&D, stability testing and regulatory support, which is exactly the layer that separates a private-label launch that clears customs cleanly from one that gets flagged.

The Big Three, and Why They’re Not Always the Right Answer

Cosmax, Kolmar and Intercos dominate industry coverage because their scale is genuinely remarkable — and because most of that scale is irrelevant to a brand placing its first order.

Manufacturer	Headquarters	Known for	Practical fit
Cosmax	South Korea	K-beauty formulation depth — sheet masks, essences, multi-step regimens; Guangzhou facility alone can produce up to 400 million units annually	Mid-to-large volume brands needing global distribution scale
Kolmar	South Korea	Pharmaceutical-grade production standards; strong in anti-aging, sun care, clinical claims support	Brands needing stability testing and clinical substantiation at volume
Intercos	Italy	Texture and sensorial R&D, strong color-cosmetics crossover	European prestige positioning, established brands

All three carry ISO 22716 certification as a baseline, and all three set MOQs that start around 5,000 units and scale up from there. For a brand testing a new SKU or launching its first line, that minimum is frequently the actual barrier — not formulation capability, not compliance, but order volume math that doesn’t work yet.

This is where a right-sized CDMO — one with its own formula library, its own compliance support, and MOQs in the hundreds to low thousands — is the more useful comparison point than the household names.

ISO 22716: The One Certification That Should End the Conversation

ISO 22716 is the international Good Manufacturing Practice standard specific to cosmetics. It governs personnel training, premises and equipment, raw material and finished product control, production, quality control, storage, and traceability — the operational backbone that makes consistent, safe batches possible.

• It is not optional. A manufacturer without ISO 22716 certification is operating without the audited GMP framework that most retailers, and most countries’ regulators, expect as a baseline.
• It is verifiable. Ask for the certificate directly — it names the certifying body, the scope of certification, and an expiry date. A vague “we follow GMP practices” without a named certification is not the same claim.
• It doesn’t stand alone. ISO 22716 covers manufacturing process control. It does not substitute for product-specific safety assessment (the EU’s CPSR) or for market-specific regulatory listing (US FDA/MoCRA).

The Compliance Layer: MoCRA and EC 1223/2009

This is where private-label skincare gets meaningfully more complex than it did five years ago, and where a private label skincare manufacturer’s regulatory support becomes a genuine differentiator rather than a nice-to-have.

Market	Governing framework	What it requires
United States	MoCRA (Modernization of Cosmetics Regulation Act), FDA	Facility registration, product listing, adverse event reporting, and — for many product types — safety substantiation on file
European Union	Regulation (EC) 1223/2009	A Cosmetic Product Safety Report (CPSR) prepared by a qualified safety assessor, CPNP notification before sale, and a Responsible Person established in the EU
Both	—	These are separate, non-overlapping requirements. Compliance in one market does not carry over to the other.

A manufacturer that offers to help navigate MoCRA listing or EU CPSR preparation is signaling real regulatory infrastructure. A private label skincare manufacturer that shrugs off the question, or claims a product is “already compliant everywhere,” is a warning sign — global blanket compliance claims don’t exist because the frameworks aren’t harmonized.

The Formulation Brief That Gets a Real Quote

1. Product category and format — serum, cream, lotion, cleanser, toner, mask; each has different base cost, stability-testing requirements and shelf-life expectations.
2. Active ingredient targets — specific actives (retinol, vitamin C, niacinamide, peptides) or a functional claim (brightening, barrier repair, anti-aging) for the formulator to work from.
3. Texture and sensory reference — a lightweight gel-cream versus a rich occlusive balm changes the base formulation entirely, even for the same active.
4. Packaging format — dropper bottle, airless pump, jar, tube — which affects both preservative system requirements and per-unit cost.
5. Claims you intend to make — “clinically tested,” “dermatologist tested,” “reduces wrinkles in 4 weeks” each carry different substantiation burdens that should be scoped before formulation, not after.
6. Target markets — determines which regulatory pathway (MoCRA, EC 1223/2009, or both) applies and who needs to prepare which documentation.
7. MOQ and timeline — first-order minimum, reorder minimum, and whether a stability-tested shelf-life claim is needed before launch or can follow shortly after.

MOQ Reality Across the Market

Manufacturer type	Typical MOQ	Trade-off
Dropship / white-label platforms	1 unit	No customization; you’re reselling an existing formula and packaging as-is
Small-batch private label labs	50–500 units	Fast, flexible, but limited formulation depth and higher per-unit cost
Right-sized CDMO with own R&D	500–2,000 units	The sweet spot for most emerging brands — real formulation input, manageable capital outlay
Cosmax, Kolmar and comparable large ODMs	5,000+ units	Full customization and clinical substantiation support, but requires committed volume

The honest advice for a brand placing a first order: match MOQ to your actual sell-through confidence, not to the lowest number a supplier will quote. A private label skincare manufacturer willing to go to 100 units on a formula they haven’t stability-tested is not doing you a favor — they’re passing you the risk of a product that hasn’t been validated to hold its claimed shelf life.

Where Zuofun Fits

Zuofun operates an in-house library of over 8,000 mature skincare formulas spanning face, body skincare and fast-moving product categories, manufactured from our Guangzhou facility with ISO-certified production. The skincare range supports both stock-formula white-label orders and custom actives-forward development.

For brands still evaluating supplier fit, our guides to choosing a private-label skincare manufacturer and beauty contract manufacturing in China cover the evaluation process for skincare specifically, alongside our private-label face serum guide for actives-driven formulations.

Frequently Asked Questions

What is ISO 22716 and why does it matter for skincare manufacturing?

ISO 22716 is the international Good Manufacturing Practice standard specific to cosmetics, covering personnel, premises, production control, quality control, storage and traceability. It is the baseline audited framework that makes consistent, safe cosmetic batches possible, and a manufacturer without current certification should be disqualified regardless of price or minimum order quantity. Always ask to see the certificate directly rather than accepting a verbal claim of GMP practices.

What’s the difference between MoCRA and EC 1223/2009 compliance?

MoCRA is the US regulatory framework administered by the FDA, requiring facility registration, product listing and adverse event reporting for cosmetics sold in the United States. EC 1223/2009 is the EU framework requiring a Cosmetic Product Safety Report prepared by a qualified assessor and CPNP notification before sale. The two are separate, non-overlapping requirements — compliance with one does not satisfy the other, and a brand selling in both markets needs both.

What MOQ should I expect for private-label skincare?

It depends heavily on private label skincare manufacturer type. Small-batch private label labs often start around 50 to 500 units. A right-sized CDMO with its own formulation R&D typically opens at 500 to 2,000 units, which suits most emerging brands. Large-scale ODMs like Cosmax and Kolmar generally require 5,000 or more units per SKU, built for brands already at commercial scale.

Should I choose Cosmax, Kolmar or a smaller CDMO for my first skincare line?

For most first-time brand launches, a smaller CDMO with its own formulation library and a realistic MOQ in the hundreds to low thousands is the better fit — the large ODMs’ minimum orders and lead times are built for brands already selling at volume. Cosmax and Kolmar become the right conversation once a brand has validated demand and is scaling production meaningfully.

How long does private-label skincare formulation and stability testing take?

Formulation from an existing base typically takes a few weeks; stability testing to substantiate a shelf-life claim commonly runs 4 to 12 weeks depending on the product type and testing protocol, and should be built into the launch timeline rather than treated as an afterthought. Actives-forward formulas, especially those with unstable ingredients like certain vitamin C forms, generally need the longer end of that range.

Can I make anti-aging or clinical claims on a private-label skincare product?

Only if the claim is substantiated with appropriate testing, and the burden of proof scales with how specific the claim is. A general “hydrating” claim requires far less substantiation than “reduces wrinkles in 4 weeks,” which typically needs clinical or consumer-perception testing behind it. Scope your intended claims during the formulation brief so the manufacturer can advise what testing is needed before launch, not after a retailer or regulator questions it.

What packaging formats affect skincare formulation the most?

Airless pumps and dropper bottles protect actives-forward formulas from oxidation better than open jars, which matters significantly for ingredients like vitamin C and retinol. Jar packaging works fine for more stable, occlusive formulas like rich creams and balms but exposes the product to more air and contamination risk over its use life, which affects preservative system requirements.

Do I need a Responsible Person to sell skincare in the EU?

Yes. EC 1223/2009 requires every cosmetic product sold in the EU to have a Responsible Person established within the EU, who takes on regulatory accountability for the product, maintains the Product Information File, and ensures the Cosmetic Product Safety Report and CPNP notification are in place before the product goes to market. This is a formal regulatory role, not just a business contact — confirm with your manufacturer or a compliance consultant who will hold it.

Conclusion

Skincare sourcing has genuinely gotten more complex, but not in a way that should intimidate a serious brand. ISO 22716 certification, MoCRA and EC 1223/2009 compliance, and stability-tested shelf-life claims are all verifiable — ask for the documents, name the standard, and treat a supplier who can’t produce them as disqualified rather than negotiable.

Beyond compliance, the sizing decision matters more than brand-name recognition. A CDMO whose MOQ, formula library and regulatory support actually match your order volume will get a real product to market faster than a household name whose minimums are built for a different stage of business entirely.